EBioMedicine · 2021 · 68 citations · 37 references
Veterinary MedicineImmunologyInfectious DiseasesHemodialysisImmunizationVaccinologyHumoral ImmunityImmunosuppressionVaccinationAntibody-mediated Virus NeutralizationImmunoglobulin QuantificationInterferon ProductionInterferon-gamma ResponsesSars-cov-2 InfectionType I Interferon ResponsesVaccination-induced Antibody ResponsesVaccine Response Serology
BACKGROUND: Patients with chronic renal insufficiency on maintenance haemodialysis face an increased risk of COVID-19 induced mortality and impaired vaccine responses. To date, only a few studies have addressed SARS-CoV-2 vaccine elicited immunity in this immunocompromised population. METHODS: We assessed immunogenicity of the mRNA vaccine BNT162b2 in at-risk dialysis patients and characterised systemic cellular and humoral immune responses in serum and saliva using interferon γ release assay and multiplex-based cytokine and immunoglobulin measurements. We further compared binding capacity and neutralization efficacy of vaccination-induced immunoglobulins against emerging SARS-CoV-2 variants Alpha, Beta, Epsilon and Cluster 5 by ACE2-RBD competition assay. FINDINGS: Patients on maintenance haemodialysis exhibit detectable but variable cellular and humoral immune responses against SARS-CoV-2 and variants of concern after a two-dose regimen of BNT162b2. Although vaccination-induced immunoglobulins were detectable in saliva and plasma, both anti-SARS-CoV-2 IgG and neutralization efficacy was reduced compared to a vaccinated non-dialysed control population. Similarly, T-cell mediated interferon γ release after stimulation with SARS-CoV-2 spike peptides was significantly diminished. INTERPRETATION: Quantifiable humoral and cellular immune responses after BNT162b2 vaccination in individuals on maintenance haemodialysis are encouraging, but urge for longitudinal follow-up to assess longevity of immunity. Diminished virus neutralization and interferon γ responses in the face of emerging variants of concern may favour this at-risk population for re-vaccination using modified vaccines at the earliest opportunity. FUNDING: Initiative and Networking Fund of the Helmholtz Association of German Research Centres, EU Horizon 2020 research and innovation program, State Ministry of Baden-Württemberg for Economic Affairs, Labour and Tourism.
37
Factors associated with COVID-19-related death using OpenSAFELY
Elizabeth Williamson, Alex J Walker, Krishnan Bhaskaran et al. · Nature · 2020 · 6.7K citations · Full text
Veterinary Medicine, Infectious Diseases, Clinical Epidemiology +6
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Uğur Şahin, Alexander Muik, Evelyna Derhovanessian et al. · Nature · 2020 · 2K citations · Full text
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Delphine Sterlin, Alexis Mathian, Makoto Miyara et al. · Science Translational Medicine · 2020 · 1.1K citations · Full text
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
Dami A. Collier, Isabella A.T.M. Ferreira, Prasanti Kotagiri et al. · Nature · 2021 · 818 citations · Full text